Please Wait
Applying Filters...

Annual Sales of Levalbuterol Hydrochloride reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Menu
$ API Ref.Price (USD/KG) : 12,414Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 5Xopenex

PharmaCompass

01

Brand Name : Xopenex

Levalbuterol

arrow
AAPS 2024
Not Confirmed

Brand Name : Xopenex

arrow
AAPS 2024
Not Confirmed

Levalbuterol

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2020 Revenue in Millions : 47

2019 Revenue in Millions : 40

Growth (%) : 20

blank

02

Brand Name : Xopenex

Levalbuterol

arrow
AAPS 2024
Not Confirmed

Brand Name : Xopenex

arrow
AAPS 2024
Not Confirmed

Levalbuterol

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2016 Revenue in Millions : 50

2015 Revenue in Millions : 61

Growth (%) : -18

blank

03

Brand Name : Xopenex

Levalbuterol

arrow
AAPS 2024
Not Confirmed

Brand Name : Xopenex

arrow
AAPS 2024
Not Confirmed

Levalbuterol

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2017 Revenue in Millions : 67

2016 Revenue in Millions : 102

Growth (%) : -34

blank

04

Brand Name : Xopenex

Levalbuterol

arrow
AAPS 2024
Not Confirmed

Brand Name : Xopenex

arrow
AAPS 2024
Not Confirmed

Levalbuterol

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2018 Revenue in Millions : 41

2017 Revenue in Millions : 36

Growth (%) : 15%

blank

05

Brand Name : Xopenex

Levalbuterol

arrow
AAPS 2024
Not Confirmed

Brand Name : Xopenex

arrow
AAPS 2024
Not Confirmed

Levalbuterol

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2019 Revenue in Millions : 38

2018 Revenue in Millions : 43

Growth (%) : -11

blank